🇺🇸 FDA
Pipeline program

Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method

261201

Phase 3 mab completed

Quick answer

Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method for Hemophilia A is a Phase 3 program (mab) at Baxalta Innovations GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Baxalta Innovations GmbH
Indication
Hemophilia A
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials